Unizithrin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unizithrin

Here is a concise overview defining the nature, classification, and general purpose of the medication known as Unizithrin.

Property Description
Active ingredient Azithromycin (INN)
Form Tablets, Oral Suspension, IV Solution, Ophthalmic Solution
Pharmacological class Macrolide Antibiotic (Azalide Subclass)
General purpose Resolves systemic bacterial infections
Origin Semisynthetic

What Type of Drug is Unizithrin? Classification and Primary Purpose

Unizithrin is a trade name for the prescription-only medicine Azithromycin (INN), which is pharmacologically recognized as a key antibiotic for treating bacterial infections where stopping the progression of bacterial growth is medically necessary. The drug is primarily categorized within the Macrolide antibiotic class, but its defining feature is its designation as an azalide. This structural distinction is chemically significant and yields a prolonged duration of action compared to older macrolides. Azithromycin achieves high tissue penetration and a long half-life, which supports its efficacy even with less frequent administration schedules.

Active Ingredient, Chemical Origin, and Available Forms

The medication is supplied as a single active ingredient product, consisting solely of Azithromycin combined with various excipients necessary for formulation. Chemically, Azithromycin is a semisynthetic compound, meaning its structure is derived from the foundational natural macrolide, Erythromycin. Azithromycin’s main mode of action is binding to the 50S ribosomal subunit of bacteria, thereby inhibiting protein synthesis. The medication is supplied across diverse preparations for various routes of administration, including tablets for oral use, powder for oral suspension, and a sterile solution for intravenous injection, ensuring its utility in different patient care settings.

What side effects are possible with Unizithrin?

Adverse Reactions and Safety Warnings

Unizithrin (azithromycin) is generally well-tolerated, with most common adverse effects being mild and related to the gastrointestinal system.

Common Side Effects

The most frequent adverse reactions reported in clinical trials (incidence of 1% or greater) are diarrhea or loose stools, nausea, abdominal pain, and vomiting. These effects are typically mild and transient.

Serious and Clinically Significant Adverse Reactions

Despite the mild nature of the common side effects, several rare but serious, potentially fatal adverse reactions have been documented in regulatory information and post-marketing surveillance:

  • Cardiovascular Risks: The drug can cause prolongation of the QT interval, which may lead to a life-threatening, irregular heart rhythm known as Torsades de Pointes and, rarely, acute cardiovascular death. The risk is noted to be greatest during the first 5 days of use.
  • Hepatotoxicity: Severe, sometimes fatal, hepatic failure and hepatitis have been reported. The drug is contraindicated in patients with a history of cholestatic jaundice or liver dysfunction associated with prior use.
  • Hypersensitivity and Skin Reactions: Serious, potentially fatal allergic reactions have occurred, including anaphylaxis, angioedema, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  • Exacerbation of Myasthenia Gravis: The medication may worsen muscle weakness in individuals with Myasthenia Gravis.
  • Clostridioides difficile-Associated Diarrhea (CDAD): Diarrhea, which can range from mild to fatal colitis, has been reported with use.
  • Infantile Hypertrophic Pyloric Stenosis (IHPS): This condition has been reported in neonates (treatment up to 42 days of life) following administration.

Safety Considerations

The drug is contraindicated in patients with a known history of hypersensitivity to macrolides or prior azithromycin-associated hepatic dysfunction. Caution and specialized monitoring are required for individuals with known QT prolongation, certain other cardiac conditions, or uncorrected low potassium or magnesium levels.

Overdose and Emergency Response

Overdose: When to Seek Help

Unizithrin (azithromycin) is an antibiotic, and while overdosage is uncommon, it can lead to acute symptoms. The expected clinical manifestations of an acute overdose are primarily linked to the gastrointestinal system and auditory function, including severe nausea, vomiting, and diarrhoea. Additionally, reversible loss of hearing has been documented in overdose cases.

Required Emergency Actions

If an overdose is suspected, immediate medical attention is essential.

Urgent medical services (e.g., 911 or local emergency number) should be called immediately if the individual shows signs of severe systemic effects, such as:

  • Collapse or fainting.
  • Seizures.
  • Trouble breathing.
  • Inability to be awakened or extreme drowsiness.

In less severe, but still concerning, overdose situations, contact a poison control center for guidance. The management of an overdose typically involves general symptomatic treatment and supportive measures as required by the patient’s condition. This may include the use of medicinal charcoal or gastric lavage in a healthcare setting to limit drug absorption.

Therapeutic Uses of Unizithrin

Unizithrin (containing azithromycin) is a medication applied in addressing certain bacterial infections. It belongs to the macrolide class of antibiotics and is commonly used to help with symptoms related to certain infectious processes.

Azithromycin is used to treat certain bacterial infections in the body's respiratory system, skin, and reproductive organs. It may assist with easing symptoms related to systemic imbalance and physical discomfort in clinical contexts involving conditions such as bronchitis, pneumonia, ear infections, strep throat, and specific sexually transmitted diseases (STDs). It is commonly used across conditions presenting with acute episodes where bacterial activity leads to **systemic or localized discomfort.

This medication is categorized as a macrolide antibiotic. It is relevant in contexts involving heightened systemic burden and provides support that helps ease the overall symptom burden. It supports general well-being during phases when symptoms become more noticeable due to bacterial activity, helping patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Symptoms related to Physical Discomfort

Regulatory References

  1. Azithromycin is used to treat certain bacterial infections

Eligibility and Restrictions for Use

The eligibility for using Unizithrin (Azithromycin) is determined by official regulatory criteria, which define both eligible populations and those for whom use is prohibited or restricted.

Contraindicated Populations

Unizithrin must not be used by patients with a known hypersensitivity to azithromycin, erythromycin, or any other macrolide or ketolide antibiotic. Use is also prohibited for patients with a history of cholestatic jaundice or liver dysfunction specifically linked to previous azithromycin treatment.

Age and Health Restrictions

Age Group Eligibility Status Condition-Based Restrictions
Adults / Older Adults Generally permitted. Caution is required for those with pre-existing QT prolongation, Torsades de Pointes history, or severe uncompensated heart failure. Older adults may be more susceptible to arrhythmias.
Pediatric Patients Established for children 6 months of age and older for most approved uses. Safety is not established for infants under 6 months. Use in neonates (under 42 days) is associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Eligibility is further restricted for those with severe renal impairment (GFR <10 mL/min) and patients with Myasthenia Gravis (risk of exacerbation). The medication's use during pregnancy is permitted only if the benefit clearly outweighs the potential risk, and small amounts pass into milk during lactation, requiring infant monitoring.

What should I know about interactions with other medicines?

Unizithrin Interactions with other medicines and products

The official regulatory profile details interaction patterns primarily based on pharmacokinetic and pharmacodynamic outcomes.


Contraindicated Combinations

Co-administration with medicinal products known to prolong the QT interval is formally contraindicated due to the documented additive risk of cardiac arrhythmia. This pharmacodynamic restriction applies to agents like Pimozide, Cisapride, and specific Class IA and Class III antiarrhythmics.


Exposure and Timing Restrictions

A significant pharmacokinetic interaction occurs with Nelfinavir, resulting in a documented increase in Azithromycin serum concentrations (Cmax and AUC). This necessitates close monitoring for known adverse reactions. Conversely, Antacids containing aluminum or magnesium decrease the peak plasma level of oral Azithrin and require a mandatory dose separation of approximately two hours.


Potentiation and Substrate Effects

The profile notes a risk of pharmacodynamic potentiation with oral anticoagulants like Warfarin, where co-administration may increase coagulation times. Azithromycin may also increase the serum levels of P-glycoprotein substrates such as Digoxin and Colchicine. This interaction structure defines all significant exposure modifications, timing constraints, and additive risks.

Mechanism of Action

The action of Azithromycin (Unizithrin) is driven by a primary inhibitory effect on bacterial replication and a secondary modulating influence on host inflammatory pathways.

Blocking the Bacterial Protein Factory

The drug’s core mechanism is the selective inhibition of microbial protein synthesis. Azithromycin binds reversibly to the 23S rRNA within the bacterial 50S ribosomal subunit, physically obstructing the ribosomal exit tunnel. This blockade halts the necessary elongation (translocation) step, instantly preventing the bacteria from producing the essential proteins required for their growth and survival. The resulting physiological consequence is a bacteriostatic effect that suppresses bacterial proliferation, which results in the inhibition of microbial proliferation against which the host immune system can act.

Modulating Host Inflammatory Signals

Beyond its primary function, Azithromycin engages a secondary immunomodulatory mechanism within host tissues. It affects local signaling pathways by suppressing the activation and migration of certain inflammatory cells and by reducing the expression of pro-inflammatory cytokines like IL-8. This action helps to temper certain inflammatory responses, contributing to the modulation of localized physiological responses within the targeted pathways.

Dosage and Administration Information

Official Administration Guidelines for Unizithrin (Azithromycin)

Unizithrin (Azithromycin) must be administered strictly according to official labeling, defining the authorized routes, dosage, and administration context. The medication is primarily available for Oral use (tablets, suspension) and Intravenous (IV) use, with some topical applications (e.g., ophthalmic) also approved.


Standard Labeled Dosing Regimens

Dosing is typically once daily over short courses, though single doses and weekly schedules exist. The total dose is often 1,500 mg, administered as:

Regimen Type Adult Dosing Schedule (Example) Duration Pattern
5-Day Course 500 mg on Day 1, followed by 250 mg daily Total 5 days
3-Day Course 500 mg once daily 3 consecutive days
Single Dose 1,000 mg or 2,000 mg single oral dose 1 day

Administration Instructions and Constraints

Oral forms (tablets and standard suspension) may be taken with or without food. However, the extended-release oral suspension must be taken on an empty stomach (at least one hour before or two hours after a meal). Doses for children (6 months and older) are calculated based on body weight (mg/kg).

For initial IV therapy, the required 500 mg once daily dose must be administered as a slow infusion after mandatory reconstitution and dilution, and must not be given as a rapid bolus or intramuscular injection. IV therapy must be followed by oral administration to complete the full treatment course duration.

Recent Clinical Evidence

Unizithrin: Recent Clinical Evidence

Clinical research on Unizithrin (an Azalide-class antibiotic) focuses on both its antibacterial efficacy in respiratory and other infections and its anti-inflammatory and immunomodulatory properties in chronic diseases. Evidence is primarily derived from randomized controlled trials (RCTs) and systematic reviews.


Overview of Clinical Trial Findings

Studies have investigated Unizithrin's role in the management of acute respiratory tract infections (URTIs). Data analyses, often from real-life settings, reported a significant reduction in the proportion of patients showing symptoms like sore throat and fever, alongside improvement in clinical signs within a short course of treatment.

Research on Long-Term Outcomes

For chronic lung conditions, research has explored the effect of long-term administration. Meta-analyses of RCTs in patients with Chronic Obstructive Pulmonary Disease (COPD) or Cystic Fibrosis (CF) suggest an association between long-term use and a reduced frequency of acute exacerbations and a slower decline in lung function in certain patient subgroups. Researchers note that the benefits must be balanced against the potential for antimicrobial resistance.


Safety Profile Highlights

Clinical trials consistently monitor the occurrence of adverse events. The drug is generally associated with a low incidence of adverse reactions in short-term use. The most frequently reported adverse events are gastrointestinal in nature (e.g., abdominal pain, nausea, and diarrhea).

However, long-term administration has been associated with specific risks. Systematic reviews focusing on extended treatment duration have reported a relationship between chronic Unizithrin use and an increased risk of bacterial macrolide resistance and, in some studies, impairment of hearing.

Adverse Event Category Short-Term Trial Frequency Long-Term Administration Note
Gastrointestinal Symptoms Common Generally low incidence; monitored closely
Hearing Impairment Rare Increased risk observed in some long-term studies
Macrolide Resistance Low Increased risk reported with continuous, extended therapy

Key Studies & References

  1. Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations
  2. Azithromycin in the Management of Upper Respiratory Tract Infections (Short-course efficacy study)

Frequently Asked Questions (FAQ)

Common questions about Unizithrin (FAQ)


Q: What is the longest amount of time people usually take Unizithrin for?

Standard courses of treatment for Unizithrin typically range from 3 to 10 days. Official product information indicates that for specific, approved long-term conditions, such as the prevention or treatment of certain serious bacterial infections, the drug may be prescribed for long-term daily or weekly administration. The precise duration is typically determined through consultation with a healthcare professional based on the specific indication.


Q: Why do some people experience diarrhea when taking Unizithrin?

Diarrhea is described in regulatory documents as a common gastrointestinal side effect of Unizithrin and other antibiotics. This often occurs because the medication, while targeting harmful bacteria, can also disrupt the balance of helpful bacteria that normally reside in the gut. In some cases, diarrhea can be a symptom of a more serious, specific bacterial imbalance.


Q: What should be done if a rash appears while using Unizithrin?

A rash is a known sign of serious hypersensitivity reactions, such as Stevens-Johnson Syndrome, associated with this medication. Official guidance advises that if a rash appears, especially if accompanied by fever, blisters, or flu-like symptoms, it is important to seek prompt medical attention. These symptoms are recognized as potentially severe and requiring urgent attention.


Q: How long does Unizithrin stay in the body after the last dose?

Official pharmacological data indicates that Azithromycin, the active ingredient in Unizithrin, has a long elimination half-life of approximately 68 hours. Due to the drug's slow release from the tissues where it concentrates, it takes about 15.5 days (or 5.5 half-lives) for the medication to be fully eliminated from the body.


Q: Can Unizithrin be used to treat viral infections like the common cold?

Unizithrin is classified as an antibiotic specifically designed to treat bacterial infections. According to official health authorities, antibiotics are not effective against infections caused by viruses, such as the common cold, flu, or viral chest infections. Using antibiotics inappropriately does not help viral infections and can contribute to antimicrobial resistance.


Q: Why is Unizithrin often given for respiratory infections?

Regulatory research highlights that Azithromycin achieves and maintains high concentrations within lung tissue, often at levels significantly exceeding those in the blood. This favorable concentration profile in the respiratory system is the main pharmacological reason that supports its approved use for treating various respiratory tract infections.


Q: What are the long-term effects of using Unizithrin frequently?

Official regulatory sources and long-term studies have identified specific risks associated with frequent or extended administration of Unizithrin. These include a heightened risk of developing macrolide-resistant bacteria. Some systematic reviews also suggest an association between long-term use and an increased risk of hearing impairment.


Q: What happens if I stop taking Unizithrin before the prescribed time?

Official patient instructions emphasize the importance of completing the full course of medicine as prescribed by a healthcare professional. Stopping the treatment early, even if symptoms appear to improve, could allow the original infection to return or may contribute to the development of drug-resistant bacteria.


Q: Does alcohol interact negatively with Unizithrin?

Official warnings generally state that Unizithrin does not have a direct, dangerous pharmacological interaction with alcohol. However, alcohol consumption may intensify some of the known side effects of the drug, such as dizziness, nausea, and headache. Official guidance notes that avoiding alcohol may help to minimize some potential side effects and support the recovery process.


Q: Is it okay to take Unizithrin with common painkillers like ibuprofen?

Regulatory interaction charts do not typically show a direct interaction between Unizithrin and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, due to the potential for Unizithrin to affect the heart, liver, or kidneys in susceptible individuals, it is important to discuss any existing heart, liver, or kidney conditions with a healthcare professional before combining medications.


Q: What happens if a dose of Unizithrin is missed?

Official patient information includes specific instructions for managing a missed dose, which depend on the type of regimen prescribed. This guidance ensures treatment effectiveness is maintained and advises against making up for the missed dose by taking a larger quantity. For personalized guidance on how to proceed, patients should refer to the instructions provided by their pharmacist or prescribing physician.


Q: What conditions is Unizithrin specifically NOT approved to treat?

Regulatory authorities have reviewed the use of azithromycin for certain conditions outside of the primary approved indications. For example, some regulatory bodies have issued cautions regarding its use for conditions like moderate acne vulgaris or for eradicating Helicobacter pylori, noting that efficacy has not been clearly established for all non-approved uses.


Q: Can Unizithrin make you sensitive to sun exposure?

Yes, this medication can cause increased sensitivity to sunlight, a condition known as photosensitivity. If sun exposure cannot be avoided while using this medication, official patient information advises safety precautions such as using protective clothing, sunglasses, and a broad-spectrum sunscreen.


Q: Why is Unizithrin called a 'macrolide'?

Unizithrin is categorized as an azalide, which is chemically a subclass of macrolide antibiotics. This classification is determined by the drug’s chemical structure, specifically the presence of a methyl-substituted nitrogen atom incorporated into its lactone ring.


Q: Is there a generic version of Unizithrin available?

The active pharmaceutical ingredient in Unizithrin, Azithromycin, is widely available from various manufacturers in generic formulations. The availability of generic options depends on the local regulatory approvals in different regions.


Q: Does Unizithrin affect birth control pills?

Official guidance states that Unizithrin does not directly stop hormonal contraceptives, such as birth control pills, from working. However, severe gastrointestinal side effects like vomiting or persistent diarrhea caused by the antibiotic may affect the proper absorption of oral contraceptives.


Q: Why is Unizithrin used to treat some sexually transmitted diseases (STDs)?

Unizithrin is specifically approved by regulatory bodies for the treatment of certain sexually transmitted infections. These indications include infections caused by Chlamydia trachomatis (urethritis/cervicitis) and Haemophilus ducreyi (chancroid).


Q: Does Unizithrin interact with supplements or vitamins?

Official interaction warnings are primarily focused on other prescription medications and antacids containing aluminum or magnesium, which require specific dosing separation. Regulatory charts do not typically list specific interactions with common dietary vitamins or general supplements.


Q: Are there any official restrictions on driving or operating machinery while using Unizithrin?

Official guidance states that Unizithrin may cause side effects such as dizziness or fainting in some individuals. If these effects occur, official patient information cautions against driving or operating machinery until the symptoms have completely stopped.


Q: Is it normal to feel tired or dizzy after taking Unizithrin?

Official patient information reports that dizziness is a possible adverse effect of this medication. Fatigue is also a reported side effect, although unusual or extreme tiredness can be a potential sign of a more serious, specific adverse reaction like liver injury or severe dehydration.


Q: Do official documents recommend avoiding grapefruits or citrus while on Unizithrin?

While not listed as a primary contraindication, some drug interaction databases indicate that grapefruit may have a minor effect on the way the body processes azithromycin. There is no major regulatory warning advising strict avoidance of citrus or grapefruit products.


Q: Is there a known issue with Unizithrin and tendon problems?

Unizithrin belongs to the macrolide class of antibiotics, and official safety warnings do not include issues with tendon problems (tendonitis or rupture). This specific safety concern is associated with a different class of antibiotics known as fluoroquinolones.


Q: Can Unizithrin be used for acne or skin conditions?

Unizithrin is officially approved for treating uncomplicated infections involving the skin and underlying structures. Some regulatory authorities have provided specific warnings or cautions regarding its use for conditions like moderate acne vulgaris where evidence of long-term effectiveness is less clear.


Q: Is Unizithrin considered a broad-spectrum antibiotic?

Yes, Azithromycin, the active ingredient in Unizithrin, is officially recognized as a broad-spectrum macrolide antibiotic. This means the drug is effective against a wide range of bacteria, including various Gram-positive and Gram-negative types.


Q: Why do some people say Unizithrin is a 'Z-pak'?

'Z-pak' is a commonly used brand name and patient slang term that refers to a specific, pre-packaged 5-day course of azithromycin. This dosing structure is recognized in regulatory guidelines as a standard labeled regimen for several infections.


Q: Can Unizithrin be taken alongside medications for high blood pressure?

Many common high blood pressure medications (antihypertensives) are not listed as having a direct interaction with Unizithrin. The primary cardiac concern is when Unizithrin is taken with certain other medications that are specifically known to prolong the heart's QT interval, which can increase the risk of an irregular heart rhythm.


How should Unizithrin be stored and disposed of?

Storage Requirements

Formulation Required Storage Condition Stability/Shelf-Life Constraint
Tablets & Dry Powder Controlled Room Temperature: 15 C to 30 C (59 F to 86 F) Store in original packaging.
Constituted Suspension Store between 5 C and 30 C (41 F to 86 F) Discard unused portion after 10 days.

Azithromycin tablets and the dry powder for suspension must be stored at room temperature, while the prepared liquid suspension has a maximum storage limit of 10 days. The medicine must be kept out of the reach of children. Any unused portion of the liquid suspension remaining after treatment is completed, or after 10 days, must be properly discarded according to the official instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unizithrin found in:

A-Z Index: